Published on : Aug 11, 2017
Albany, New York, August 11, 2017: The topic of Hypogonadism can be an embarrassing subject for an affected male. Nevertheless, it's important that any man battling the symptoms of Hypogonadism to get over his embarrassment and be taken care of by a medical professional. A new pipeline study, related to the therapeutics activities for male hypogonadism has been recently broadcasted to the wide repository of Market Research Hub (MRH), with the title of “Male Hypogonadism-Pipeline Insight, 2017”. The study highlights the pharmacological action of various therapeutics and their history of research and development activities.
Male hypogonadism is defined as the failure of the testes to produce androgen, sperm or both. Although the disorder is extremely common, its exact prevalence is uncertain. It is a condition in which the body doesn't produce enough testosterone, the hormone that plays a key role in masculine growth and development during puberty. It may adversely affect multiple organ functions and quality of life. Signs and symptoms depend on when the condition develops. The research analyses its symptoms, which include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). When hormone levels decline, men can easily experience significant psychological and physical changes.
Moreover, this study provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The coverage of pipeline products based on the numerous stages of development ranging from early development to approved or issued stage. In this subsequent section, details of foremost pipeline products which includes, product description, licensing and collaboration details and other developmental activities are also mentioned. This study has been built using proprietary databases along with latest updates and featured news & press releases from various university sites and industry-specific third party sources.
Looking to the therapeutics overview, the research studies that the levels of testosterone in men start to fall after the age of 40. It has been estimated that 8.4% of men aged 50–79 years have testosterone deficiency. Some types of male hypogonadism can be treated with testosterone replacement therapy. There is a lot of research in progress to find out more about the effects of testosterone in older men and also whether the use of testosterone replacement therapy would have any benefits.
For a competitive analysis, the research has listed key companies operating in the market, focusing on their research and development efforts, adoption to changing trends and their efforts to discover new therapeutics for male hypogonadism. Also, the report covers dormant and discontinued pipeline projects related to the Male Hypogonadism. With this information, the new entrants in the market can modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1265411
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com